Expression of 11β-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer

1998 ◽  
Vol 67 (4) ◽  
pp. 341-346 ◽  
Author(s):  
Lee L. Parks ◽  
Maxine K. Turney ◽  
Daniel Gaitan ◽  
William J. Kovacs
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Hydroxysteroid Dehydrogenase ◽  
Small Cell ◽  
Small Cell Lung

Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer

Lung Cancer ◽  
2015 ◽  
Vol 87 (2) ◽  
pp. 107-116 ◽  
Author(s):  
Hanna Drzewiecka ◽  
Bartłomiej Gałęcki ◽  
Donata Jarmołowska-Jurczyszyn ◽  
Andrzej Kluk ◽  
Wojciech Dyszkiewicz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Hydroxysteroid Dehydrogenase ◽  
Small Cell ◽  
Small Cell Lung

Prognostic factors for resected non-small cell lung cancer in patients with type 2 diabetes mellitus

2018 ◽  
Vol 117 (5) ◽  
pp. 985-993 ◽  
Author(s):  
Woo Sik Yu ◽  
Chang Young Lee ◽  
Seong Yong Park ◽  
Jee Won Suh ◽  
Kyoung Shik Narm ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lung Cancer ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Acute worsening of glycemic control in a patient with type 2 diabetes and non-small cell lung cancer after administration of lorlatinib

2021 ◽  
Author(s):  
Yoshio NAKANO ◽  
Mai MIYASATO-ISODA ◽  
Iwao GHOMA ◽  
Tomomi FUJISAWA
Keyword(s):  
Lung Cancer ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Glucose Monitoring ◽  
Small Cell ◽  
Diabetes Treatment ◽  
Small Cell Lung

A case with non-small cell lung cancer exhibited extreme hyperglycemia after lorlatinib treatment, whose adverse effects on hyperglycemia is little known. But, the lorlatinib could be continued by intensifying diabetes treatment, indicating the importance of glucose monitoring during lorlatinib administration, and of adequate intensification of treatment for such hyperglycemia.

scholarly journals The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to Gq, Gi and G12 proteins

Oncogene ◽  
2000 ◽  
Vol 19 (37) ◽  
pp. 4199-4209 ◽  
Author(s):  
Norbert Wittau ◽  
Robert Grosse ◽  
Frank Kalkbrenner ◽  
Antje Gohla ◽  
Günter Schultz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Galanin Receptor ◽  
Multiple Signaling
Sign in / Sign up

Export Citation Format

Share Document